StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) Remdesivir Data Looks Encouraging, But Many Unknowns Remain - RBC Capital
April 17, 2020 7:48 AM
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $85.00 price target on Gilead Sciences (NASDAQ: GILD) but remains ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments